| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.094 | 0.02 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.15 | 0.02 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.088 | 0.02 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.02 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |